Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | OT |
vaccine HIB was improperly stored and administered to 2 unknown demographic patients; Initial information received on 15-Jan-2026 regarding an unsolicited non-valid non-serious case received from a other health professional. This case involves an unknown age and unknown gender two patients who were administered with HAEMOPHILUS TYPE B (HIB) VACCINE that was improperly stored with no ae (adverse event). The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the unknown age and unknown gender two patients of suspect HAEMOPHILUS TYPE B (HIB) VACCINE produced by unknown manufacturer (strength, expiry date and lot number not reported) via unknown route in unknown administration site for Prophylactic vaccination (Immunisation) that was improperly stored with no ae (poor quality product administered) (latency-same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.